COVID-19NCT04477889
Methodist Health System COVID-19 Patient Registry
An observational study of COVID-19, run by Methodist Health System at 1 site in United States.
Trial summary
This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- What is being tested?
- Treatment for COVID-19
- How many people
- 550 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Jun 2020to 16 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All adult patients who are treated at MHS facilities for COVID-19.
Who may be able to join
- Patient tested positive for COVID-19 (SARS-CoV-2)
- Patient sought care for COVID-19 at a MHS facility
- Aged 18 years or older
Who cannot join
- Patient that do not have COVID-19
- Non-confirmed COVID-19 patients
- Aged 17 years or younger
Trial locations and contacts
1 site in 1 country.
United States1 site
Clinical Research Institute Methodist Health System
Dallas, Texas, 75203
About this study
This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19.
Read the detailed description
This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19. Data including, but not limited to demographics, comorbidities, medications, treatment, and clinical outcomes will be collected from February 2020 to December 2025. Subjects will undergo no additional tests or procedures as part of this registry study. All patient data will be obtained from the patient's electronic health records (EHR) of the hospital or clinic in a retrospective manner. The process for gathering the data will not influence treatment decisions. There will be no direct patient contact associated with inclusion in this registry study.
- Conditions
- COVID-19
- Being tested
- Treatment for COVID-19
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment for COVID-19Other
Patients treated for COVID-19
| Study group | Role | What they receive |
|---|---|---|
| COVID-19 Cohort | Patients treated at MHS facilites for COVID-19 Receives: Other: Treatment for COVID-19 | |
| Synopsis for COVID Bariatric, Hepato-Biliary and Colorectal surgery study | 30 Day Mortality after surgery in patients with COVID19 infection who undergo elective bariatric, hepato-biliary and colorectal surgery.
* Patients diagnosed with COVID-19 at the time of surgery up to seven days before surgery
* Patients diagnosed with COVID-19 within 30 days after surgery Receives: Other: Treatment for COVID-19 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Characteristics
Patient characteristics
Measured: June 2020 - Dec 2025
Treatment Measures and Intervention strategies
Treatment measures and intervention strategies
Measured: June 2020 - Dec 2025
Clinical and survival outcomes
Clinical and survival outcomes
Measured: June 2020 - Dec 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2020
- Study start20 Jun 2020
- Primary completion16 Jun 2025
- Study completion16 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 550 participants (actual)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Crystee Cooper, DHEd, Principal investigator, Methodist Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04477889
- Sponsor's protocol ID
- 024.CRI.2020.A
- Status last verified
- May 2026
- First submitted
- 17 Jul 2020
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Methodist Health System COVID-19 Patient Registry
- ClinicalTrials.gov ID
- NCT04477889
- Acronym / sponsor ID
- 024.CRI.2020.A
- Conditions
- COVID-19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 550 participants (actual)
- Lead sponsor
- Methodist Health SystemUniversity, hospital or other
- Study start
- 20 Jun 2020 (actual)
- Primary completion
- 16 Jun 2025 (actual)
- Study completion
- 16 Jun 2025 (actual)
- First posted
- 20 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19.
Detailed description
This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19. Data including, but not limited to demographics, comorbidities, medications, treatment, and clinical outcomes will be collected from February 2020 to December 2025. Subjects will undergo no additional tests or procedures as part of this registry study. All patient data will be obtained from the patient's electronic health records (EHR) of the hospital or clinic in a retrospective manner. The process for gathering the data will not influence treatment decisions. There will be no direct patient contact associated with inclusion in this registry study.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| COVID-19 Cohort | – | Other: Treatment for COVID-19Patients treated at MHS facilites for COVID-19 |
| Synopsis for COVID Bariatric, Hepato-Biliary and Colorectal surgery study | – | Other: Treatment for COVID-1930 Day Mortality after surgery in patients with COVID19 infection who undergo elective bariatric, hepato-biliary and colorectal surgery. * Patients diagnosed with COVID-19 at the time of surgery up to seven days before surgery * Patients diagnosed with COVID-19 within 30 days after surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All adult patients who are treated at MHS facilities for COVID-19.
Key inclusion criteria (3 listed)
- Patient tested positive for COVID-19 (SARS-CoV-2)
- Patient sought care for COVID-19 at a MHS facility
- Aged 18 years or older
Key exclusion criteria (3 listed)
- Patient that do not have COVID-19
- Non-confirmed COVID-19 patients
- Aged 17 years or younger
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment for COVID-19Patients treated for COVID-19 | Other | COVID-19 Cohort, Synopsis for COVID Bariatric, Hepato-Biliary and Colorectal surgery study |
Primary outcome
Patient Characteristics
Time frame: June 2020 - Dec 2025
Patient characteristics
Treatment Measures and Intervention strategies
Time frame: June 2020 - Dec 2025
Treatment measures and intervention strategies
Clinical and survival outcomes
Time frame: June 2020 - Dec 2025
Clinical and survival outcomes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
ARDS, Covid19
Active, not recruitingObservational study
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
COVID-19, Vaccination
RecruitingPhase 4
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
COVID -19, COVID - 19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
COVID-19, SARS-CoV-2 Infection, RSV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Crystee Cooper, DHEd principal investigator
Methodist Health System
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Methodist Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Characteristics (time frame: June 2020 - Dec 2025). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.